Allergan Wins Federal Approval for Non-Animal Testing Protocol of Botox©
Calvert Investments and the Humane Society of the United States congratulate Allergan, manufacturer of Botox©, for developing an animal-free, FDA-approved test after years of negotiation
The Humane Society of the United States (HSUS) and Calvert Investments applaud Allergan’s announcement that the company has developed—and received federal approval for—a new procedure that avoids using animals in testing batches of Botox© products.
The industry standard for assessing the potency and stability of Botox-like products has been the LD50 test, which subjects animals to considerable suffering and results in death by asphyxiation. According to an Allergan press release, the company spent more than 10 years and $65 million conducting research to develop the new test and secured approval from the U.S Food and Drug Administration on June 24th. The company expects the new method will reduce its use of animals in Botox© testing by 95 percent within three years.
Allergan also disclosed that the development of the new test was cost-neutral. Calvert believes that from an investor perspective, consumer-facing products such as Botox© may actually benefit from brand enhancements involving reduced or no-animal testing.
“CEO David Pyott has delivered on his promise that Allergan would invest the money and expertise necessary to develop an animal-free method of testing batches of Botox©,” stated Martin Stephens, Ph.D., vice president for animal research issues for The HSUS. “We now urge Allergan to work with companies that manufacture products with active ingredients similar to that used in Botox©, to see if the new method can be tailored to those products, thereby sparing additional animals. In the European Union alone, tens of thousands of animals are estimated to be used in this testing per year, and this use has been increasing.”
“We commend Allergan on gaining regulatory approval in the United States for its new test and we welcome the FDA’s approval of the alternative method,” stated Ellen Kennedy, senior sustainability analyst for Calvert Investments, which joined the HSUS in co-filing shareholder resolutions with Allergan to ensure the company’s commitment to progress on this issue. “We urge Allergan to move expeditiously to secure approvals in Botox© markets outside of the United States.”
1927: The LD50 test is developed to assess the potency and safety of therapeutic agents that vary from batch to batch. “LD50” stands for Lethal Dose-50 percent and, in a typical LD50 test, around half the animals will die from the effects of the test agent.
2003: An exposé by the Fund for the Replacement of Animals in Medical Experiments (UK) indicates that the LD50 test, which is otherwise waning, is used to standardize batches of Botox© and similar products, the demand for which has been growing.
2004: The HSUS approaches Allergan about its use of animals in Botox© testing in January of 2004, asking the company to replace the LD50 test with appropriate non-animal systems. In October of 2004, The HSUS appealed to its members to contact Allergan to urge the company to replace the LD50 with a non-animal alternative.
2007: Allergan posts a statement on its website about its animal testing, including for Botox©.
2008: The HSUS and Calvert Investments file a shareholder resolution urging greater transparency in Allergan’s efforts to replace the LD50 test. At the shareholder meeting, the resolution receives nearly double the number of supportive votes to allow the resolution to be re-filed in 2009.
2009: A second HSUS/Calvert resolution gains enough votes to comfortably exceed the six percent threshold to allow the resolution to be re-filed in 2010. At the shareholder meeting, Allergan CEO David Pyott affirms the company’s commitment to develop a non-animal replacement for the LD50 test.
2010: The HSUS and Calvert withdraw their third resolution after Allergan revises its website statement on Botox©testing, providing an update on its progress towards developing an alternative test and affirming in writing its commitment to finish the job.
As of 6/30/11, accounts managed by Calvert Investment Management, Inc. held securities issued by Allergan Inc. Calvert may or may not still invest in, and is not recommending any action on, Allergan Inc.